Calliditas Q3 update: Improved conversion rate ahead of a new Tarpeyo label - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Calliditas Q3 update: Improved conversion rate ahead of a new Tarpeyo label - Redeye

{newsItem.title}

During the 2023 Tarpeyo's conversion rate has improved gradually from low levels. Calliditas maintains the full year sales guide despite reporting slightly soft Q3 sales and points to improved activity in late Q3 and early Q4. Our take is that this is another sign of improved conversion ahead of the PDUFA date on 20th December. Our updated view is a base case valuation of SEK 280 (295) and a Bull Case of SEK 415 (445) and a Bear Case of SEK 70 (75) Considerable label and study support ahead

Länk till analysen i sin helhet: https://www.redeye.se/research/956446/calliditas-q3-update-improved-conversion-rate-ahead-of-a-new-tarpeyo-label?utm_source=finwire&utm_medium=RSS

Nyheter om Calliditas Therapeutics

Läses av andra just nu

Om aktien Calliditas Therapeutics

Senaste nytt